ロード中...
Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers
The oncogenic role ERBB2 amplification is well established in breast and gastric cancers. This has led to the development of a well‐known portfolio of monoclonal antibodies and kinase inhibitors targeting the ERBB2 kinase. More recently, activating mutations in the ERBB2 gene have been increasingly...
保存先:
| 出版年: | Oncologist |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley & Sons, Inc.
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6975965/ https://ncbi.nlm.nih.gov/pubmed/31292270 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0845 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|